La jolla pharmaceutical company to provide giapreza™ (angiotensin ii) for emergency medical program in patients with septic shock due to covid-19 at chirec delta hospital, brussels, belgium

San diego, april 13, 2020 (globe newswire) -- la jolla pharmaceutical company (nasdaq: ljpc), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing giapreza™ (angiotensin ii) for an emergency medical  program in patients with septic shock due to covid-19 at the centre hospitalier interrÉgional edith cavell (chirec) delta hospital in brussels, belgium. giapreza is being made available for emergency medical use based on a request from professor daniel de backer, m.d., head, department of intensive care, chirec delta hospital in brussels, belgium. according to belgian law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. giapreza has been recently approved by the european commission but is not yet commercially available in europe.
DAL Ratings Summary
DAL Quant Ranking